Introduction: Venous thromboembolism (VTE) is a major cause of morbidity and mortality, and individuals with a first episode of VTE are at risk of recurrent VTE. Vitamin K antagonists have been the mainstay in the treatment of VTE after an initial course of parenteral anticoagulation.Dabigatran etexilate is an orally administered direct thrombin inhibitor used in the treatment and secondary prevention of VTE and with a reduced risk for major and clinically relevant nonmajor bleeding. Materials and methods: A total of 29 patients diagnosed as DVT of the lower limb admitted from April 1, 2016 to March 31, 2019 in the Department of Surgery, Regional Institute of Medical Sciences, Imphal, India were studied. Inclusion criteria: All patients objectively diagnosed as DVT of lower limbs by Doppler ultrasonography and followed up for at least six months. Exclusion criteria: All patients objectively diagnosed as DVT of lower limbs by Doppler ultrasonography and followed up for less than three months. All patients with duration of symptoms longer than 14 days were excluded. All patients were given low molecular weight heparin for 5 days initially at the time of diagnosis followed by Tab. Dabigatran 110 mg 12 hourly for a minimum of three months. Results: A total of 29 patients of DVT of lower limbs were studied, and majority of the patients were in the age group of 46 – 88 years. After 1 year of follow up while still on Dabigatran 110 mg twice daily 9 patients (31%) had normal limb size as compared to the unaffected limb. Whereas 37% of patients are asymptomatic except slightly increased limb size. Conclusion: Dabigatran and other non–vitamin K oral anticoagulants are occasionally used off-label in patients with DVT. Dabigatran is noninferior to warfarin for the prevention of recurrent VTE. The risk for clinically relevant bleeding or any bleeding is significantly lower with Dabigatran.